A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids.
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
InMed is utilizing its proprietary bioinformatics assessment tool to identify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases. Our Bioinformatics Tool has been used to identify two new drug candidates that optimize therapeutic benefits of cannabinoids while limiting adverse effects.
InMed’s proprietary: in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.
InMed’s Core Assets
Proprietary computer-based drug/disease target screening tool.
Proprietary cannabinoid manufacturing system.
Drug Development Pipeline
Expedited Drug Development timelines, conservative clinical budget targeting high unmet medical conditions utilizing disease-specific formulations:
|Extensive portfolio of assets in dermatology, ocular diseases, additional indications as well as cannabinoid biosynthesis|
Set to achieve value-driving, near-term milestones with limited investment:
Experienced team capable of building value in biopharmaceuticals
Compared to peers in the cannabinoid drug development and epidermolysis bullosa space, InMed is has an attractive valuation
Download our Corporate Presentation.